Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI and glucose monitors may predict surgery risks for rare tumors

NCT ID NCT07516275

Knowledge-focused Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will enroll 200 patients scheduled for surgery to remove rare adrenal tumors called pheochromocytomas or paragangliomas (PPGL). Before surgery, researchers will use a model to predict the risk of severe blood pressure swings during the operation. During surgery, a real-time early warning tool will be tested to see if it can predict blood pressure changes 60 seconds ahead. The study also tests continuous glucose monitors and an AI agent for preoperative assessment, but does not change standard care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to better prediction and real-time warning of dangerous blood pressure changes during surgery, making the operation safer for patients.
What could go wrong
This is an early observational study, not a treatment trial. The models may not be accurate enough to change practice, and results may not apply to other hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients diagnosed with pheochromocytoma or paraganglioma scheduled for elective surgical resection at Peking Union Medical College Hospital.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years. * Diagnosed with pheochromocytoma/paraganglioma by imaging and laboratory tests and scheduled for elective resection. * Planned intraoperative continuous invasive arterial pressure monitoring. * Willing and able to provide written informed consent. * Able to comply with preoperative CGM monitoring, AI agent assessment, and postoperative follow-up. Exclusion Criteria: * Intraoperative hemodynamic data missing ≥20%. * Postoperative histopathology excludes PPGL diagnosis. * Cardiac paraganglioma or metastatic PPGL. * Severe cardiac disease (e.g., severe valvular disease, severe heart failure) that could independently cause intraoperative HDI. * Pregnancy or breastfeeding. * Mental illness, cognitive impairment, or communication barriers that prevent compliance with study procedures. * Refusal to undergo CGM monitoring or AI agent assessment. * Major illness (e.g., acute myocardial infarction, stroke, severe infection) within 3 months prior to surgery. * Severe hepatic or renal insufficiency (Child-Pugh class C, eGFR \<30 ml/min/1.73 m²).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hemodynamic instability are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Intraoperative Complications paraganglioma pheochromocytoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hemodynamic instability Intraoperative complications Paraganglioma Pheochromocytoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.